المؤلفون: Pan M; School of Pharmacy, China Pharmaceutical University, Nanjing, China., Lin Y; Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China., Liu Y; School of Pharmacy, China Pharmaceutical University, Nanjing, China., Xu R; Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. jean0129@163.com., Yang J; School of Pharmacy, China Pharmaceutical University, Nanjing, China. cpu_yj@163.com.; Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China. cpu_yj@163.com.

المصدر: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2024 Sep; Vol. 80 (9), pp. 1387-1397. Date of Electronic Publication: 2024 Jun 20.

نوع المنشور: Journal Article; Meta-Analysis

بيانات الدورية: Publisher: Springer Country of Publication: Germany NLM ID: 1256165 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1041 (Electronic) Linking ISSN: 00316970 NLM ISO Abbreviation: Eur J Clin Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Receptor, ErbB-2*/metabolism , Receptor, ErbB-2*/antagonists & inhibitors , Cyclin-Dependent Kinase 4*/antagonists & inhibitors , Cyclin-Dependent Kinase 6*/antagonists & inhibitors, Humans ; Female ; TOR Serine-Threonine Kinases/antagonists & inhibitors ; Receptors, Estrogen/metabolism ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/administration & dosage ; Proto-Oncogene Proteins c-akt/antagonists & inhibitors ; Proto-Oncogene Proteins c-akt/metabolism ; Antineoplastic Agents, Hormonal/therapeutic use ; Antineoplastic Agents, Hormonal/administration & dosage ; Antineoplastic Agents, Hormonal/adverse effects ; Phosphoinositide-3 Kinase Inhibitors/therapeutic use ; Phosphoinositide-3 Kinase Inhibitors/administration & dosage ; Progression-Free Survival ; Neoplasm Metastasis

المؤلفون: Wang M; Department of Nephrology, First Hospital of China Medical University, Shenyang, Liaoning, China., Huang Z; Department of Nephrology, First Hospital of China Medical University, Shenyang, Liaoning, China., Li X; Department of Nephrology, Fourth Hospital of China Medical University, Shenyang, Liaoning, China., He P; Department of Nephrology, First Hospital of China Medical University, Shenyang, Liaoning, China., Sun H; Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China., Peng Y; Department of Nephrology, First Hospital of China Medical University, Shenyang, Liaoning, China., Fan Q; Department of Nephrology, First Hospital of China Medical University, Shenyang, Liaoning, China; Department of Nephrology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: cmufql@163.com.

المصدر: Pharmacological research [Pharmacol Res] 2024 Sep; Vol. 207, pp. 107306. Date of Electronic Publication: 2024 Jul 11.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8907422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-1186 (Electronic) Linking ISSN: 10436618 NLM ISO Abbreviation: Pharmacol Res Subsets: MEDLINE

مواضيع طبية MeSH: Pyroptosis*/drug effects , Cell Cycle Proteins*/metabolism , Diabetic Nephropathies*/drug therapy , Diabetic Nephropathies*/metabolism , Diabetic Nephropathies*/pathology , Proto-Oncogene Proteins*/metabolism , Proto-Oncogene Proteins*/antagonists & inhibitors , Polo-Like Kinase 1* , Protein Serine-Threonine Kinases*/metabolism , Protein Serine-Threonine Kinases*/antagonists & inhibitors , Mice, Inbred C57BL* , Transcription Factors*/metabolism, Animals ; Humans ; Cell Line ; Mice ; Male ; Histones/metabolism ; NLR Family, Pyrin Domain-Containing 3 Protein/metabolism ; NLR Family, Pyrin Domain-Containing 3 Protein/antagonists & inhibitors ; E1A-Associated p300 Protein/metabolism ; E1A-Associated p300 Protein/antagonists & inhibitors ; Kidney/drug effects ; Kidney/pathology ; Kidney/metabolism ; Signal Transduction/drug effects ; Inflammasomes/metabolism ; Inflammasomes/drug effects ; Bromodomain Containing Proteins ; Nuclear Proteins

المؤلفون: Raičević V; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.

المصدر: Drug design, development and therapy [Drug Des Devel Ther] 2024 Aug 30; Vol. 18, pp. 3923-3924. Date of Electronic Publication: 2024 Aug 30 (Print Publication: 2024).

نوع المنشور: Letter; Journal Article

بيانات الدورية: Publisher: Dove Press Limited Country of Publication: New Zealand NLM ID: 101475745 Publication Model: eCollection Cited Medium: Internet ISSN: 1177-8881 (Electronic) Linking ISSN: 11778881 NLM ISO Abbreviation: Drug Des Devel Ther Subsets: MEDLINE

مواضيع طبية MeSH: Signal Transduction*/drug effects , LIM Domain Proteins*/metabolism , LIM Domain Proteins*/antagonists & inhibitors , Mouth Neoplasms*/drug therapy , Mouth Neoplasms*/metabolism , Mouth Neoplasms*/pathology , Adaptor Proteins, Signal Transducing*/metabolism , Adaptor Proteins, Signal Transducing*/antagonists & inhibitors, Humans ; Cytoskeletal Proteins/metabolism ; Cytoskeletal Proteins/antagonists & inhibitors ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/chemistry ; Janus Kinases/antagonists & inhibitors ; Janus Kinases/metabolism ; Cell Proliferation/drug effects ; STAT Transcription Factors/metabolism ; STAT Transcription Factors/antagonists & inhibitors ; Disease Progression ; Drug Screening Assays, Antitumor

المؤلفون: Jess J; Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, Michigan., Sorensen KM; Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, Michigan., Boguslawski EA; Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, Michigan.; Division of Oncology, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Stout MC; Division of Oncology, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Madaj ZB; Bioinformatics and Biostatistics Core, Van Andel Research Institute, Grand Rapids, Michigan., Caiello BP; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Pomaville M; Division of Oncology, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Wilson ER; Division of Oncology, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Kinn-Gurzo SS; Division of Oncology, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Parker CC; Division of Oncology, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Veluvolu SM; Division of Oncology, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Brysgel TV; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Kaufman R; Division of Oncology, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Kitchen-Goosen SM; Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, Michigan., Gedminas JM; Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, Michigan.; Division of Oncology, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Grohar PJ; Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, Michigan.; Division of Oncology, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Aug 15; Vol. 30 (16), pp. 3533-3548.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Sarcoma, Ewing*/drug therapy , Sarcoma, Ewing*/pathology , Sarcoma, Ewing*/genetics , Cisplatin*/pharmacology , Ataxia Telangiectasia Mutated Proteins*/antagonists & inhibitors , RNA-Binding Protein EWS*/genetics , RNA-Binding Protein EWS*/antagonists & inhibitors , Drug Synergism* , Xenograft Model Antitumor Assays* , Proto-Oncogene Protein c-fli-1*/genetics , Proto-Oncogene Protein c-fli-1*/antagonists & inhibitors, Humans ; Animals ; Mice ; Cell Line, Tumor ; Oncogene Proteins, Fusion/genetics ; Oncogene Proteins, Fusion/antagonists & inhibitors ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Checkpoint Kinase 1/antagonists & inhibitors ; DNA Damage/drug effects ; Gene Expression Regulation, Neoplastic/drug effects ; Isoxazoles ; Pyrazines

المؤلفون: Beyaoui A; University of Monastir, Faculty of Science of Monastir, Laboratory of Heterocyclic Chemistry, Natural Products and Reactivity (LR11ES39), Team: Medicinal Chemistry and Natural Products, Avenue of Environment, 5019, Monastir, Tunisia., Kaplan M; TUBITAK Marmara Research Centre, Institute of Chemical Technology, 41470, Gebze, Kocaeli, Turkiye., Saidi I; University of Monastir, Faculty of Science of Monastir, Laboratory of Heterocyclic Chemistry, Natural Products and Reactivity (LR11ES39), Team: Medicinal Chemistry and Natural Products, Avenue of Environment, 5019, Monastir, Tunisia., Jalouli M; Department of Biology, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, 11623, Saudi Arabia., Ceyhan Goren A; Gebze Technical University, Faculty of Basic Sciences, Department of Chemistry, Gebze, Kocaeli, Turkiye., Halim Harrath A; Department of Zoology, College of Science, King Saud University, Riyadh, 11451, Saudi Arabia., Ben Jannet H; University of Monastir, Faculty of Science of Monastir, Laboratory of Heterocyclic Chemistry, Natural Products and Reactivity (LR11ES39), Team: Medicinal Chemistry and Natural Products, Avenue of Environment, 5019, Monastir, Tunisia.

المصدر: Chemistry & biodiversity [Chem Biodivers] 2024 Aug; Vol. 21 (8), pp. e202401061. Date of Electronic Publication: 2024 Jul 04.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Verlag Helvetica Chimica Acta Country of Publication: Switzerland NLM ID: 101197449 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1612-1880 (Electronic) Linking ISSN: 16121872 NLM ISO Abbreviation: Chem Biodivers Subsets: MEDLINE

مواضيع طبية MeSH: Plant Bark*/chemistry , Phenols*/chemistry , Phenols*/pharmacology , Phenols*/isolation & purification , alpha-Amylases*/antagonists & inhibitors , alpha-Amylases*/metabolism , Molecular Docking Simulation* , Acacia*/chemistry , Antioxidants*/pharmacology , Antioxidants*/chemistry , Antioxidants*/isolation & purification , Monophenol Monooxygenase*/antagonists & inhibitors , Monophenol Monooxygenase*/metabolism , Plant Extracts*/chemistry , Plant Extracts*/pharmacology , Plant Extracts*/isolation & purification , Enzyme Inhibitors*/pharmacology , Enzyme Inhibitors*/chemistry , Enzyme Inhibitors*/isolation & purification, Picrates/antagonists & inhibitors ; Biphenyl Compounds/antagonists & inhibitors ; Computer Simulation ; Flavonoids/chemistry ; Flavonoids/pharmacology ; Flavonoids/isolation & purification

المؤلفون: Graham K; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany; Nuvisan ICB GmbH, Muellerstr. 178, 13353 Berlin, Germany., Lienau P; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany., Bader B; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany; Nuvisan ICB GmbH, Muellerstr. 178, 13353 Berlin, Germany., Prechtl S; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany; Nuvisan ICB GmbH, Muellerstr. 178, 13353 Berlin, Germany., Naujoks J; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany; Nuvisan ICB GmbH, Muellerstr. 178, 13353 Berlin, Germany., Lesche R; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany; Nuvisan ICB GmbH, Muellerstr. 178, 13353 Berlin, Germany., Weiske J; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany; Nuvisan ICB GmbH, Muellerstr. 178, 13353 Berlin, Germany., Kuehnlenz J; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany., Brzezinka K; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany; Nuvisan ICB GmbH, Muellerstr. 178, 13353 Berlin, Germany., Potze L; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany., Zanconato F; Department of Molecular Medicine, University of Padua, Via Gabelli 63, 35121 Padua, Italy., Nicke B; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany; Nuvisan ICB GmbH, Muellerstr. 178, 13353 Berlin, Germany., Montebaur A; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany., Bone W; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany; Nuvisan ICB GmbH, Muellerstr. 178, 13353 Berlin, Germany., Golfier S; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany; Nuvisan ICB GmbH, Muellerstr. 178, 13353 Berlin, Germany., Kaulfuss S; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany; Nuvisan ICB GmbH, Muellerstr. 178, 13353 Berlin, Germany., Kopitz C; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany; Nuvisan ICB GmbH, Muellerstr. 178, 13353 Berlin, Germany., Pilari S; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany., Steuber H; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany; Nuvisan ICB GmbH, Muellerstr. 178, 13353 Berlin, Germany., Hayat S; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany., Kamburov A; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany., Steffen A; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany., Schlicker A; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany., Buchgraber P; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany., Braeuer N; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany; Nuvisan ICB GmbH, Muellerstr. 178, 13353 Berlin, Germany., Font NA; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany., Heinrich T; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany., Kuhnke L; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany., Nowak-Reppel K; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany; Nuvisan ICB GmbH, Muellerstr. 178, 13353 Berlin, Germany., Stresemann C; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany; Nuvisan ICB GmbH, Muellerstr. 178, 13353 Berlin, Germany., Steigemann P; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany; Nuvisan ICB GmbH, Muellerstr. 178, 13353 Berlin, Germany., Walter AO; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany., Blotta S; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany., Ocker M; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany., Lakner A; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany., von Nussbaum F; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany; Nuvisan ICB GmbH, Muellerstr. 178, 13353 Berlin, Germany., Mumberg D; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany., Eis K; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany., Piccolo S; Department of Molecular Medicine, University of Padua, Via Gabelli 63, 35121 Padua, Italy; IFOM, the FIRC Institute of Molecular Oncology, Via Adamello 16, 20139 Milan, Italy., Lange M; Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany; Nuvisan ICB GmbH, Muellerstr. 178, 13353 Berlin, Germany. Electronic address: martin.lange@nuvisan.com.

المصدر: Cell chemical biology [Cell Chem Biol] 2024 Jul 18; Vol. 31 (7), pp. 1247-1263.e16. Date of Electronic Publication: 2024 Mar 26.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101676030 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2451-9448 (Electronic) Linking ISSN: 24519448 NLM ISO Abbreviation: Cell Chem Biol Subsets: MEDLINE

مواضيع طبية MeSH: Transcription Factors*/metabolism , Transcription Factors*/antagonists & inhibitors , YAP-Signaling Proteins*/metabolism , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemistry , Antineoplastic Agents*/chemical synthesis , Signal Transduction*/drug effects , Adaptor Proteins, Signal Transducing*/metabolism , Adaptor Proteins, Signal Transducing*/antagonists & inhibitors , Cell Proliferation*/drug effects , High-Throughput Screening Assays*, Humans ; Animals ; Mice ; rho GTP-Binding Proteins/metabolism ; rho GTP-Binding Proteins/antagonists & inhibitors ; Cell Line, Tumor ; Phosphoproteins/metabolism ; Phosphoproteins/antagonists & inhibitors ; Drug Screening Assays, Antitumor ; Alkyl and Aryl Transferases/antagonists & inhibitors ; Alkyl and Aryl Transferases/metabolism ; Small Molecule Libraries/chemistry ; Small Molecule Libraries/pharmacology ; Drug Discovery ; Mice, Nude ; Acyltransferases/antagonists & inhibitors ; Acyltransferases/metabolism ; Phenotype ; Structure-Activity Relationship ; Transcriptional Coactivator with PDZ-Binding Motif Proteins

المؤلفون: Gobbo F; Department of Veterinary Medical Sciences, Alma Mater Studiorum University, 40126 Bologna, Italy., Martelli F; National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, 00161 Rome, Italy., Di Virgilio A; National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, 00161 Rome, Italy., Demaria E; Department of Medical and Surgical Sciences, Alma Mater Studiorum University, 40126 Bologna, Italy., Sarli G; Department of Veterinary Medical Sciences, Alma Mater Studiorum University, 40126 Bologna, Italy., Migliaccio AR; Altius Institute for Biomedical Sciences, Seattle, WA 98121, USA.; Institute of Nanotechnology, National Research Council (Cnr-NANOTEC), c/o Campus Ecotekne, 73100 Lecce, Italy.

المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Jul 13; Vol. 25 (14). Date of Electronic Publication: 2024 Jul 13.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

مواضيع طبية MeSH: Primary Myelofibrosis*/drug therapy , Primary Myelofibrosis*/metabolism , Primary Myelofibrosis*/pathology , Transforming Growth Factor beta*/metabolism , Janus Kinase 1*/antagonists & inhibitors , Janus Kinase 1*/metabolism , P-Selectin*/metabolism , Receptors, Interleukin-8B*/antagonists & inhibitors , Receptors, Interleukin-8B*/metabolism , Pyrimidines*/pharmacology , Pyrimidines*/therapeutic use, Animals ; Receptors, Interleukin-8A/antagonists & inhibitors ; Receptors, Interleukin-8A/metabolism ; Mice ; Janus Kinase 2/metabolism ; Janus Kinase 2/antagonists & inhibitors ; Nitriles/therapeutic use ; Nitriles/pharmacology ; Disease Models, Animal ; Drug Therapy, Combination ; GATA1 Transcription Factor/metabolism ; GATA1 Transcription Factor/genetics ; Pyrazoles/pharmacology ; Pyrazoles/therapeutic use ; Humans

المؤلفون: Nozaki Y; Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan., Akiba H; Department of Immunology, Juntendo University, School of Medicine, Bunkyo-ku, Tokyo, Japan., Akazawa H; Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan., Yamazawa H; Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan., Ishimura K; Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan., Kinoshita K; Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan., Matsumura I; Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.

المصدر: Clinical and experimental immunology [Clin Exp Immunol] 2024 Sep 16; Vol. 218 (1), pp. 55-64.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 0057202 Publication Model: Print Cited Medium: Internet ISSN: 1365-2249 (Electronic) Linking ISSN: 00099104 NLM ISO Abbreviation: Clin Exp Immunol Subsets: MEDLINE

مواضيع طبية MeSH: Hepatitis A Virus Cellular Receptor 2*/metabolism , Hepatitis A Virus Cellular Receptor 2*/antagonists & inhibitors , Hepatitis A Virus Cellular Receptor 1*/metabolism , Arthritis, Rheumatoid*/immunology , Arthritis, Rheumatoid*/drug therapy , Arthritis, Rheumatoid*/metabolism , Signal Transduction* , Disease Models, Animal*, Animals ; Mice ; Female ; Interleukin-6/metabolism ; Interleukin-6/antagonists & inhibitors ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Tumor Necrosis Factor-alpha/metabolism ; Interleukin-17/metabolism ; Interleukin-17/antagonists & inhibitors ; Arthritis, Experimental/immunology ; Arthritis, Experimental/metabolism

المؤلفون: Wei D; School of Pharmacy, Shenzhen University Medical School, Shenzhen 518055, China., Cai J; School of Pharmacy, Shenzhen University Medical School, Shenzhen 518055, China., Qin F; School of Pharmacy, Shenzhen University Medical School, Shenzhen 518055, China., Zhou Q; School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen 518055, China., Xiong W; School of Pharmacy, Shenzhen University Medical School, Shenzhen 518055, China., Xu C; School of Pharmacy, Shenzhen University Medical School, Shenzhen 518055, China., Li C; School of Pharmacy, Shenzhen University Medical School, Shenzhen 518055, China. Electronic address: lcy@szu.edu.cn., Wu H; School of Pharmacy, Shenzhen University Medical School, Shenzhen 518055, China. Electronic address: wuhq@szu.edu.cn.

المصدر: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2024 Sep 15; Vol. 110, pp. 129851. Date of Electronic Publication: 2024 Jun 19.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9107377 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1464-3405 (Electronic) Linking ISSN: 0960894X NLM ISO Abbreviation: Bioorg Med Chem Lett Subsets: MEDLINE

مواضيع طبية MeSH: Maleimides*/chemistry , Maleimides*/pharmacology , Maleimides*/chemical synthesis , Imidazoles*/chemistry , Imidazoles*/pharmacology , Imidazoles*/chemical synthesis , Glycogen Synthase Kinase 3 beta*/antagonists & inhibitors , Glycogen Synthase Kinase 3 beta*/metabolism , Aminoacyltransferases*/antagonists & inhibitors , Aminoacyltransferases*/metabolism, Structure-Activity Relationship ; Humans ; Enzyme Inhibitors/chemistry ; Enzyme Inhibitors/pharmacology ; Enzyme Inhibitors/chemical synthesis ; Molecular Structure ; Alzheimer Disease/drug therapy ; Glycogen Synthase Kinase 3/antagonists & inhibitors ; Glycogen Synthase Kinase 3/metabolism ; Dose-Response Relationship, Drug

المؤلفون: Jeon SH; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.; Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea., You G; ABL Bio Inc., Seongnam, Republic of Korea., Park J; Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Republic of Korea., Chung Y; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea., Park K; ABL Bio Inc., Seongnam, Republic of Korea., Kim H; ABL Bio Inc., Seongnam, Republic of Korea., Jeon J; ABL Bio Inc., Seongnam, Republic of Korea., Kim Y; ABL Bio Inc., Seongnam, Republic of Korea., Son WC; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Jeong DS; Department of Medical Science, AMIST, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Shin EC; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea., Lee JY; Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Republic of Korea., Han DH; Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea., Jung J; ABL Bio Inc., Seongnam, Republic of Korea., Park SH; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Sep 13; Vol. 30 (18), pp. 4155-4166.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Bispecific*/pharmacology , Antibodies, Bispecific*/therapeutic use , CD8-Positive T-Lymphocytes*/immunology , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/immunology , Lymphocytes, Tumor-Infiltrating*/immunology , Lymphocytes, Tumor-Infiltrating*/drug effects , Tumor Necrosis Factor Receptor Superfamily, Member 9*/antagonists & inhibitors , Tumor Necrosis Factor Receptor Superfamily, Member 9*/immunology , Immune Checkpoint Inhibitors*/pharmacology , Immune Checkpoint Inhibitors*/therapeutic use, Animals ; Humans ; Mice ; Female ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/immunology ; Xenograft Model Antitumor Assays ; Cell Line, Tumor ; Ovarian Neoplasms/immunology ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/pathology ; Ovarian Neoplasms/therapy ; Carcinoma, Hepatocellular/drug therapy ; Carcinoma, Hepatocellular/immunology ; Carcinoma, Hepatocellular/pathology ; Carcinoma, Hepatocellular/therapy ; Liver Neoplasms/immunology ; Liver Neoplasms/drug therapy ; Liver Neoplasms/pathology